Finally, the ChEA performed on CD34+ cells derived from CML patients after in vitro Imatinib treatment suggest important findings: only a few lists of deregulated genes emerge between the two specimens (not treated and Imatinib treatment), and the presence of Sox2, Nanog, and OCT 3/4 make our assumptions even more meaningful since they are validated on a tool of human samples [25,28]. This evidence concerns the gene CD34 and chronic myelogenous leukemia, BCR-ABL1 positive.